1. INTRODUCTION {#sec1}
===============

Intestinal ischemia occurs when there is an interruption of the blood supply to the intestine, or when there is inadequate organ perfusion due to conditions of shock or hypovolemia \[[@B1]\]. It is also an unavoidable condition during transplant and other surgical procedures, such as aortic repair. The initial damage caused by ischemia is further worsened by reperfusion. This entity is known as ischemia/reperfusion (I/R) injury. I/R can adversely affect transplant outcomes and induces a systemic life-risking inflammatory response. I/R injury is mediated by multiple mechanisms such as production of reactive oxygen species, intravascular thrombosis, inflammatory cell infiltration, and cytokine production \[[@B2]\]. Rodent models of intestinal I/R are useful in order to study the physiopathological mechanisms of I/R injury as well as in the search for much needed novel protective strategies \[[@B1]\]. In this study, we evaluated the value of triflusal (TRI), S-adenosylmethionine (SAME), and dextromethorphan (DEX) over intestinal I/R injury. All of these agents are currently in clinical use.

TRI is an antiplatelet drug related to but not derived from acetylsalicylic acid, that acts through the modulation of thromboxane synthesis but also possesses neuroprotective, antioxidant, and anti-inflammatory properties \[[@B3]\]. TRI has been shown to decrease cerebral I/R injury and to prevent ischemia-induced cytokine expression in neural cells \[[@B4]\]. SAME is an amino acid that serves as a precursor to glutathione, a major physiological antioxidant, and serves an important function in opposing free radial production and oxidative stress generated by various pathological processes \[[@B5]\]. SAME has been shown to reduce brain and liver I/R injury, through decreased lipid peroxidation and induction of antioxidant defenses \[[@B6], [@B7]\]. DEX is a antitussive and neuroprotective agent and a low-affinity N-methyl-D-aspartate (NMDA) receptor channel blocker. Studies have demonstrated that DEX protects the brain against I/R injury \[[@B8]\]. In one recent study, DEX was able to reduce intestinal I/R-induced lung injury in a rodent model \[[@B9]\]. To the best of our knowledge, the protective effects of these drugs against intestinal I/R injury have not been studied before.

2. METHODS {#sec2}
==========

Animal procedures were performed in accordance with the proper use and care of laboratory animals, approved by the ethics committee of our institution. Experiments were performed on 25 male Wistar rats weighing 200--250 g. Animals were maintained under standard conditions, such as stable room temperature (24 ± 3°), a 12 h light/12 h dark cycle, and access to commercial rat pellets and water *ad libitum*. Briefly, after pentobarbital sodium anesthesia (Anestesal, Pfizer Inc, Mexico) (35 mg/kg, i.p), a midline laparotomy was performed. Animals were placed under heating lamp in order to preserve core body temperature at (37°). Ischemia was induced by cross-clamping the superior mesenteric artery for 60 min (ischemia), and removed to allow 60 min of reperfusion.

Drug dosages and time of administration were decided based on published literature and on dose-response trials performed previously in our laboratory (unpublished data). Rats were randomly divided into five groups (*n* = 5): (1) a sham-operated group (Sham), where laparotomy was performed but intestines were only manipulated but not made ischemic, (2) a control (CTL) group that was subjected to I/R as described above, (3) a TRI group, that received 100 mg/kg of TRI daily, for three days before I/R, (4) a SAME group, that received 100 mg/kg of SAME 1 h before surgery, and (5) a DEX group that received 100 mg/kg of DEX 1 h before surgery. All drugs were administered orally via gavage.

2.1. Tissue Examination {#sec2.1}
-----------------------

Immediately after concluding the reperfusion period, rats were sacrificed by exsanguination from the aorta and intestinal tissue samples were obtained. The samples were then fixed in 10% neutral buffered formalin overnight, embedded in paraffin, and 4 *μ*m-thick sections were stained with hematoxylin and eosin (H/E) and examined under light microscope by a blinded pathologist. The Chiu score of mucosa injury was used to evaluate the degree of histological damage in the intestine, as detailed elsewhere \[[@B10]\]. The scale consists of values from of 0 to 5, where 0 normal mucosa; 1 development of subepithelial (Gruenhagen\'s) spaces; 2 extension of the subepithelial space with moderate epithelial lifting from the lamina propria; 3 extensive epithelial lifting with occasional denuded villi tips; 4 denuded villi with exposed lamina propria and dilated capillaries; 5 disintegration of the lamina propria, hemorrhage, and ulceration.

2.2. Serum Analysis {#sec2.2}
-------------------

Blood samples were used to determine serum levels of AST (aspartate-aminotransferase), ALT (alanine-aminotransferase), and LDH (lactate dehydrogenase) by standard biochemical automated methods, using commercially available kits and DT6011 and DTSC11 analyzers (System Vitros Chemical, Johnson and Johnson, USA). AST and LDH plasma levels serve as indirect markers of intestinal injury, while ALT is more specific for hepatic injury. Serum concentrations of TNF-alpha were determined using a rat ELISA kit (PeproTech, Mexico). Lipid peroxidation, expressed as malonaldehyde (MDA) levels, was assessed by the TBARS method using a commercially available colorimetric assay kit (Cayman chemicals, USA). Total serum antioxidant capacity (TAC) was assessed using a commercially available colorimetric assay kit (Cayman chemicals, USA). TAC values are expressed as Trolox Equivalents (TEs).

2.3. Statistical Analysis {#sec2.3}
-------------------------

SPSS 11.0 statistical software (SPSS Inc. Software, Chicago, Ill, USA) was used to analyze data using one-way analysis of variance (ANOVA) and with LSD post hoc test (when data were found to be normally distributed) and Kruskal-Wallis test (when data were not normally distributed) so as to determine comparison between groups and differences between groups, respectively. All values are expressed as mean ± SD, and *P* \< 0.05 was considered statistically significant.

3. RESULTS {#sec3}
==========

3.1. ALT, AST, and LDH {#sec3.1}
----------------------

AST values were significantly elevated after I/R in group CTL compared to sham group, and all treatment groups had AST levels significantly lower than CTL group ([Table 1](#tab1){ref-type="table"}). LDH levels in group CTL were significantly increased compared to sham group. While groups TRI and DEX showed lower levels of LDH, levels in SAME group remained comparable to those in CTL group. After I/R, ALT values were increased in CTL group compared to sham group, but only TRI and SAME were able to reduce ALT elevations ([Table 1](#tab1){ref-type="table"}).

3.2. Morphological Examination {#sec3.2}
------------------------------

In sham group, Chiu score of mucosal injury was 1 ± 0, indicating negligible injury. In CTL group, severe mucosal injury was evident after I/R, reaching a Chiu score of 4.2 ± 0.44. In TRI group, there was some injury but it was significantly less than in CTL group (Chiu score: 2.7 ± 0.95, *P* \< 0.05, [Figure 1](#fig1){ref-type="fig"}). SAME group also showed reduced injury compared to CTL group, with Chiu score 2.5 ± 0.57 (*P* \< 0.05). DEX group showed reduced injury as well, reaching statistical significance at 3 ± 1.41 (*P* \< 0.05).

3.3. Serum TNF-Alpha {#sec3.3}
--------------------

TNF-alpha levels remained undetectable in sham group. In CTL group, TNF-alpha levels reached 2.26 ± 1 ng/mL. TRI group had undetectable TNF-alpha levels by our assay as well, significantly lower than in CTL group (*P* \< 0.05, [Figure 1](#fig1){ref-type="fig"}). The TNF-alpha levels in groups SAME and DEX were similar to those in CTL group (SAME: 4.2 ± 4.9 ng/mL; DEX: 0.74 ± 0.88 ng/mL).

3.4. MDA and TAC {#sec3.4}
----------------

Sham group had MDA concentrations of 2.56 ± 0.829 *μ*M/mL. In CTL group, MDA levels were significantly increased (7.42 ± 1.72 *μ*M/mL, *P* \< 0.05, [Figure 1](#fig1){ref-type="fig"}). All treatments were effective in reducing the elevations in serum concentrations of MDA (TRI: 1.59 ± 0.27 U/L*μ*M/mL; SAME: 3.82 ± 0.57 *μ*M/mL; DEX: 4.19 ± 2.12 *μ*M/mL, *P* \< 0.05), significantly lower to levels in CTL group. Sham group, serum TAC was 2.749 ± 0.19 TEs. In CTL group, serum antioxidants were significantly depleted (2.05 ± 0.36 TEs, *P* \< 0.05). In TRI group, serum TAC was preserved, with levels comparable to sham group and significantly higher than in CTL group (2.72 ± 0.11 TEs). In SAME group, serum TAC was actually increased compared to sham group (3.39 ± 0.43 TEs, *P* \< 0.05). However, in DEX group serum TAC showed only a trend towards higher levels when compared to CTL group (2.58 ± 0.6 TEs, *P* = 0.07).

4. DISCUSSION {#sec4}
=============

I/R injury is a potentially devastating condition, associated with many surgical pathologies, and the search for therapeutic interventions is necessary, given that there is no standard treatment at present time. In this study, we evaluated the effects of three agents, with different mechanisms of action and clinical use, over intestinal I/R injury.

TRI was very effective in reducing intestinal I/R injury, as well as the associated TNF-alpha elevations, oxidative stress markers, and liver injury, as assessed by ALT elevations. TRI is an antiplatelet drug that inhibits both cyclooxygenase-1 (COX) and 2, decreasing prostaglandin and thromboxane production. Other COX-2 inhibitors have been also shown to protect the intestine against I/R injury, albeit mildly, while COX-1 inhibitors have little effects \[[@B11]\]. More studies would be required to show if TRI could be acting through a COX-2-dependent pathway. Platelet-endothelial interactions in the intestinal microvasculature play an important pathophysiological role in I/R injury \[[@B12]\]. Additionally, it has been demonstrated that TRI potently inhibits the transcription factors nuclear factor kappaB (NF-KappaB) and nuclear factor of activated T cells, responsible for the production of many inflammatory cytokines, such as TNF-alpha \[[@B13], [@B14]\], also essential in the pathophysiology of I/R injury. In experimental models of cerebral I/R injury, TRI is effective in reducing tissue injury, through antithrombotic, antioxidant, and antiinflammatory effects \[[@B3]\]. All these mechanisms could be responsible for the results we observed in this study.

Oxidative stress is an important mediator in pathological conditions of I/R injury, and antioxidant therapy has been widely studied as a protective strategy against this condition \[[@B15]\]. SAME is a precursor of glutathione, an antioxidant. Glutathione is a powerful cytoprotectant in the intestine, and glutathione supplementation has been proposed as a promising therapy for I/R injury \[[@B16]\]. In this study, SAME reduced intestinal I/R injury, the associated transaminase elevations, lipid peroxidation, and increased serum TAC. Studies involving I/R of organs such as the brain and liver have previously shown a protective effect of SAME, attributable to inhibition of lipid peroxidation and increased levels of protective antioxidants \[[@B6], [@B7]\]. However, SAME has also been effective in reducing inflammatory damage in a rodent model of colitis \[[@B17]\], and *in vitro* studies indicate that SAME is able to modulate inflammatory cytokine production, including TNF-alpha, in inflammatory cells \[[@B18]\]. However, we found no effects of SAME over TNF-alpha serum concentrations in our study, despite tissue protection. This dissociation between TNF-alpha production, oxidative stress, and tissue injury, after SAME treatment, was described in a recent study, involving a liver I/R model. Llacuna et al. \[[@B19]\] reported that after SAME treatment, ischemic liver cells had increased expression of TNF-alpha genes, despite increased antioxidant gene expression and protection against injury, possibly because differential effects of SAME over specific cellular populations. A similar effect could explain our results.

It is known that NMDA receptors exist in the enteric nervous system and NMDA antagonists are effective in reducing the functional alterations associated with intestinal I/R \[[@B20]\]. In previous studies, we have also demonstrated that ketamine, an NMDA antagonist, could reduce intestinal I/R injury, although whether this was due to NMDA-related effects, or to ketamine\'s antiinflammatory activity, remains unclear \[[@B10], [@B19], [@B21]\]. In the present study, we found that DEX also had mild protective effects. However, studies suggest that DEX not only acts through NMDA-inhibition, and other effects, such as calcium channel inhibition, modulation of c-fos expression, and possibly antiinflammatory effects, have been reported \[[@B2], [@B9]\]. Reduced levels of TNF-alpha production, hepatoprotection, and inhibition of cytokine gene expression were observed after DEX administration in an endotoxemia model in rats \[[@B22]\], and DEX has also been demonstrated to inhibit macrophage free radical production *in vitro* \[[@B23]\]. In the present study, we found no effects of DEX treatment over either TNF-alpha levels or serum TAC, although we did find evidence of reduced lipid peroxidation. We also found no effects over ALT levels. The precise pathway involved in DEX\'s effects over I/R injury in nonnervous tissue warrants further research.

There are some limitations to this study. The drug doses used are higher than those that are clinically relevant. Furthermore, we studied acute injury and markers of inflammation and oxidative stress, but not outcome (such as mortality). We also did not study combination treatment, which we assume would be effective, since the drugs studied have different mechanisms of action. These issues require further investigation.

5. CONCLUSIONS {#sec5}
==============

The search for pleiotropic drugs, capable of modulating the physiopathological mechanisms of I/R injury, to be used as protective therapies, is an active field of research. We have proposed such an application for three drugs currently in clinical use, each with markedly different mechanisms of action.
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###### 

Serum biochemical parameters: AST, LDH, and ALT levels.

  Group   AST (U/L)            LDH (U/L)              ALT (U/L)
  ------- -------------------- ---------------------- ---------------
  Sham    145.25 ± 12.1        6080.75 ± 1042.55      52.5 ± 11
  CTL     339.2 ± 78.11\*      10309.40 ± 2240.16\*   192 ± 82.1\*
  SAME    214.25 ± 11.47\*\*   10,200 ± 1042.4 U/L    74 ± 16.9\*\*
  DEX     236.75 ± 16\*\*      7395 ± 560\*\*         176 ± 10.45
  TRI     166.75 ± 65.9\*\*    3400 ± 339\*\*         76 ± 3\*\*

\**P* \< 0.05 versus Sham; \*\**P* \< 0.05 versus CTL.

[^1]: Academic Editor: Huaxin Sheng
